Sarcopenic obesity

Noom Adds Muscle Defense™ to Its GLP-1 Companion Program to Help Prevent Muscle-Mass Loss While Taking GLP-1s

Retrieved on: 
목요일, 5월 9, 2024
Skeletal muscle, Health, Psychology, Sarcopenic obesity, Pilates, Habit, Yoga, Motivation, Exercise, Movement, Community, HIIT, Management

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better and healthier lives, launches Noom Move, an on-demand fitness offering, including Muscle Defense™, a curated movement program for those taking GLP-1 medications. In a cutting-edge collaboration with FitOn, the move directly integrates FitOn’s extensive library of fitness programming into the Noom app, making exercise available to all Noom members as they build healthy habits.

Key Points: 
  • In a cutting-edge collaboration with FitOn, the move directly integrates FitOn’s extensive library of fitness programming into the Noom app, making exercise available to all Noom members as they build healthy habits.
  • “Powerful weight-loss meds need a powerful companion,” said Geoff Cook, Chief Executive Officer of Noom.
  • “Muscle mass must be retained to avoid conditions like sarcopenic obesity down the road.
  • Noom Move makes habit-building even easier.”
    Noom Move is now available to all Noom members, including Noom Med and GLP-1 Companion members, supporting medically assisted weight loss to prevent lean muscle mass loss.

Immunis Publishes Research Showing Secretomes Improve Metabolism and Muscle While Reducing Fat in Aged Models

Retrieved on: 
화요일, 3월 19, 2024
Men, Other Health, General Health, Pharmaceutical, Consumer, Infectious Diseases, Fitness & Nutrition, Biotechnology, Women, Alternative Medicine, Seniors, Vitamins, Supplements, Health, Metabolism, Adipose tissue, Obesity, Facial muscles, Connective tissue, Blood, Immunotherapy, Inc., Weight gain, Ageing, Fracture, Research, Mouse, DSM-IV codes, Aging Cell, University, Hope, Human, Muscle atrophy, Sarcopenic obesity, Therapy, Hospital, Dietary supplement

The study, published in Aging Cell, is entitled “ Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice .” The research examines the effects of Immunis’ investigational secretome on metabolism, fat and skeletal muscle in aged mouse models.

Key Points: 
  • The study, published in Aging Cell, is entitled “ Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice .” The research examines the effects of Immunis’ investigational secretome on metabolism, fat and skeletal muscle in aged mouse models.
  • As we age, our metabolic health declines and commonly manifests as obesity, muscle atrophy, and reduced physical function.
  • Dr. Drummond’s independent research in aged mouse models shows that Immunis’ immunotherapy, IMMUNA, increases whole-body lean mass and reduces fat mass, while increasing muscle fiber area.
  • Muscle quality improved such that there was an increase in muscle ‘stem’ cells, enhanced collagen turnover, more blood vessels and decreased muscle fat.

Noom GLP-1 Companion to Add “Muscle Defense” to Promote Safer GLP-1 Use

Retrieved on: 
금요일, 1월 19, 2024
Apps, Applications, Technology, Mobile, Wireless, Fitness & Nutrition, Health Technology, Telemedicine, Virtual Medicine, Health, Pharmaceutical, General Health, Well, Mortality, Obesity, Bone density, Patient, Facial muscles, Overalls, Sarcopenic obesity, MD, Interactivity, Multimedia, Diet, Partnership, Comprehensive, Atrophy, History, Fitness, Behavior, Risk, FACP, Medicine, Conditional sentence, Insulin resistance, Dietary supplement

Noom GLP-1 Companion with Muscle Defense is aimed at helping GLP-1 users navigate one of the most problematic concerns surrounding GLP-1 use today — muscle mass loss.

Key Points: 
  • Noom GLP-1 Companion with Muscle Defense is aimed at helping GLP-1 users navigate one of the most problematic concerns surrounding GLP-1 use today — muscle mass loss.
  • To address this major concern of lost muscle mass while taking GLP-1s, Noom today announced its partnership with FitOn to launch Muscle Defense within its most recent offering: Noom GLP-1 Companion .
  • Noom GLP-1 Companion with Muscle Defense provides the protein-tracking, resistance training, behavior change, and expert guidance needed to have the best outcomes while taking a GLP-1.
  • Noom GLP-1 Companion with Muscle Defense will begin rolling out in the spring.

Liviniti Announces Noom GLP-1 Companion and Comprehensive Weight Management Solution

Retrieved on: 
화요일, 1월 9, 2024
Obesity, PBM, Patient, Sarcopenic obesity, Weight loss, Health, Partnership, Curriculum, Leanne, FACP, Disease, Insulin resistance, Exercise, Pharmaceutical industry

Liviniti adopts Noom to support sustainable weight loss and healthier outcomes.

Key Points: 
  • Liviniti is one of the first PBMs to help employers optimize outcomes in weight management through this new program.
  • "We are proud to partner with Noom to offer Liviniti clients flexible weight management solutions," says LeAnn Boyd, Liviniti CEO.
  • The collaboration with Noom for Work also includes the Noom Weight, Noom Diabetes Prevention, and Noom Mood programs that use content, community and coaching to empower members to live better, longer lives.
  • By partnering with Noom, Liviniti is one of the first PBMs to help employers optimize outcomes in weight management.

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

Retrieved on: 
월요일, 1월 8, 2024
Patient, CDC, Food, Metabolism, Risk, Overweight, IND, Weight, Gait, Weight loss, Mortality, Atrophy, Muscle weakness, Investigational New Drug, Insulin resistance, Calendar, Obesity, Facial muscles, Frailty, Safety, Adapted automobile, Sarcopenic obesity

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs are very effective drugs that result in significant weight loss.

Key Points: 
  • Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs are very effective drugs that result in significant weight loss.
  • Unfortunately, up to 50% of the total weight loss comes from muscle which is problematic as muscle is necessary for metabolism, strength, and physical function.
  • According to the CDC, 41.5% of older U.S. adults have obesity and could benefit from a weight loss medication.
  • Patients with critically low muscle mass may experience muscle weakness leading to poor balance, decreased gait speed, mobility disability, loss of independence, falls, bone fractures and increased mortality.

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasi

Retrieved on: 
수요일, 10월 4, 2023
Well, Exercise, Insulin resistance, Human, Obesity, Journal of Cachexia, Sarcopenia and Muscle, SCP, Osteoporosis, Enobosarm, Diabetes, Metabolism, Adapted automobile, Bone, Facial muscles, E pluribus unum, Weight loss, Clinical trial, Cancer, Ageing, Woman, Sarcopenic obesity, Falls, BMD, Trial of the century, Muscle weakness, Strength, Villarreal, Appendix, Bloomberg, Patient, Division, Risk, Overweight, Baylor College of Medicine, Type, Mortality, DEXA, Atrophy, Dietary supplement, Soft drink, Endocrinology

MIAMI, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, breast cancer and for viral induced ARDS, today announced that the Company will advance its proprietary novel agent, enobosarm, a selective androgen receptor modulator (SARM), into a Phase 2b clinical trial in combination with weight-loss GLP-1 drugs, Ozempic (semaglutide), Wegovy (semaglutide), or Mounjaro (tirzepatide) to evaluate the efficacy and the safety of enobosarm to further increase fat loss while preventing the significant muscle wasting that occurs with weight-loss GLP-1 drugs.

Key Points: 
  • Specifically, enobosarm therapy could augment the preferential loss of fat mass while preventing the loss of critical muscle mass and bone mineral density.
  • Enobosarm treatment could also preserve or improve muscle strength and physical function in older adults being treated with a weight loss drug.
  • The primary endpoint of the study will be change in total lean body mass (muscle) from baseline to 4 months.
  • Key secondary endpoints will be change from baseline to 4 months in total fat mass, insulin resistance (HOMA-IR), and body weight.

New Study Reveals Method Linking AMRA Medical's Muscle Biomarkers and Function

Retrieved on: 
수요일, 10월 23, 2019
Medicine, Clinical medicine, Branches of biology, Aging-associated diseases, Rehabilitation medicine, Medical signs, Geriatrics, Sarcopenia, Senescence, Biomarker, Sarcopenic obesity

Accurately assessing sarcopenia is difficult due to muscle volume and function being influenced by several factors such as age, weight, fitness, pain and disease.

Key Points: 
  • Accurately assessing sarcopenia is difficult due to muscle volume and function being influenced by several factors such as age, weight, fitness, pain and disease.
  • Fat-free muscle volume and muscle fat infiltration combined showed the highest diagnostic performance for detecting low function.
  • Combining fat-free muscle volume with muscle fat infiltration and incorporating virtual control groups increased diagnostic performance for detecting low muscle function and adjusts for BMI.
  • This method can potentially serve as a framework for clinicians and researchers to objectively detect sarcopenia using quantifiable MR imaging biomarkers.